Cassandra Calabrese
YOU?
Author Swipe
View article: Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors Open
Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and time…
View article: ABS0529 IMPACT OF ANIFROLUMAB ON DEPRESSIVE SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS FROM A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY
ABS0529 IMPACT OF ANIFROLUMAB ON DEPRESSIVE SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PRELIMINARY RESULTS FROM A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY Open
View article: ABS0670 DIFFERENTIAL EFFICACY OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS AT ONSET AND RELAPSES: AN OBSERVATIONAL STUDY
ABS0670 DIFFERENTIAL EFFICACY OF INDUCTION TREATMENTS FOR LUPUS NEPHRITIS AT ONSET AND RELAPSES: AN OBSERVATIONAL STUDY Open
View article: The National Academies’ 2024 Diagnostic Criteria for Long <scp>COVID</scp>: Concerns That Could Affect the Rheumatology Community
The National Academies’ 2024 Diagnostic Criteria for Long <span>COVID</span>: Concerns That Could Affect the Rheumatology Community Open
View article: SARS-CoV-2 ORF8 drives osteoclastogenesis in preexisting immune-mediated inflammatory diseases
SARS-CoV-2 ORF8 drives osteoclastogenesis in preexisting immune-mediated inflammatory diseases Open
Patients with immune-mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) are at higher risk for severe COVID-19 and long-term complications in bone health. Emerging clinical evidence demonstrated that SARS-CoV-2 infection…
View article: Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis
Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis Open
Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate …
View article: Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study Open
Background Patients with cancer and an underlying autoimmune disease who are considering immune checkpoint blockers (ICBs) need to know about the benefits and risks of severe immune-related adverse events and flares of the autoimmune condi…
View article: Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review
Association between myeloid disorders and adult onset-inflammatory syndromes, successful treatment with JAK-inhibitors: Case series and literature review Open
Approximately one-third of patients with myeloid disorders like myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) exhibit inflammatory and autoimmune disorders (IADs). These IADs often include atypical and incomplet…
View article: Preventing herpes zoster in immunocompromised patients: Current concepts
Preventing herpes zoster in immunocompromised patients: Current concepts Open
Herpes zoster (HZ) incidence is much higher in immunocompromised individuals than in immunocompetent individuals. HZ also occurs at a younger age and is often more severe in immunocompromised persons. Preventive strategies center around th…
View article: A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology
A scoping review of vasculitis as an immune-related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology Open
Vasculitis as an irAE appears clinically heterogeneous and rare. Among reported cases with adequate documentation, vasculitis is of delayed onset following the initiation of immunotherapy. Outcomes of ICI-vasculitis were generally favorabl…
View article: Mechanistic insights into bone remodelling dysregulation by human viral pathogens
Mechanistic insights into bone remodelling dysregulation by human viral pathogens Open
View article: The Future of COVID-19 for Patients With Immune-Mediated Inflammatory Diseases: Who Is at Risk?
The Future of COVID-19 for Patients With Immune-Mediated Inflammatory Diseases: Who Is at Risk? Open
For the rheumatologist, one of the greatest challenges since the start of the coronavirus disease 2019 (COVID-19) pandemic has been determining which of our patients are at greatest risk for severe COVID-19, and who should be triaged for a…
View article: Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation Open
View article: Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors Open
Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups o…
View article: Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021
Risk factors for severe COVID-19 among patients with systemic lupus erythematosus: a real-world analysis of a large representative US administrative claims database, 2020–2021 Open
Objectives To identify risk factors for progression to severe COVID-19 and estimate the odds of severe COVID-19 associated with vaccination among patients with systemic lupus erythematosus (SLE). Methods This retrospective cohort study ide…
View article: AB1479 TO EACH THEIR OWN- CLASSIFICATION OF ARTHRITIS PHENOTYPE AMONG INFLAMMATORY ARTHRITIS PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS
AB1479 TO EACH THEIR OWN- CLASSIFICATION OF ARTHRITIS PHENOTYPE AMONG INFLAMMATORY ARTHRITIS PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS Open
View article: OP0029 COMPARATIVE SAFETY AND EFFECTIVENESS OF TNF INHIBITORS, IL6R INHIBITORS AND METHOTREXATE FOR THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED ARTHRITIS
OP0029 COMPARATIVE SAFETY AND EFFECTIVENESS OF TNF INHIBITORS, IL6R INHIBITORS AND METHOTREXATE FOR THE TREATMENT OF IMMUNE CHECKPOINT INHIBITOR ASSOCIATED ARTHRITIS Open
View article: AB0705 LONG TERM SAFETY OF CONVENTIONAL AND BIOLOGIC IL-6RI IMMUNOMODULATORS AS SECOND-LINE (2L) OR THIRD-LINE (3L) TREATMENT OF POLYMYALGIA RHEUMATICA
AB0705 LONG TERM SAFETY OF CONVENTIONAL AND BIOLOGIC IL-6RI IMMUNOMODULATORS AS SECOND-LINE (2L) OR THIRD-LINE (3L) TREATMENT OF POLYMYALGIA RHEUMATICA Open
Background In polymyalgia rheumatica (PMR), IL-6Ri therapy has been studied in limited number of patients in RCTs, with exposure up to 16-52 weeks, [1-3] while patients may require longer treatment in real world. Data are presen…
View article: POS1560 USING SURVIVAL CLASSIFICATION AND REGRESSION TREES AND SURVIVAL RANDOM FOREST TO INVESTIGATE ASSOCIATIONS AMONG FACTORS FOR CANCER PROGRESSION AND ARTHRITIS CONTROL IN A MULTI-CENTER RETROSPECTIVE COHORT OF PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS
POS1560 USING SURVIVAL CLASSIFICATION AND REGRESSION TREES AND SURVIVAL RANDOM FOREST TO INVESTIGATE ASSOCIATIONS AMONG FACTORS FOR CANCER PROGRESSION AND ARTHRITIS CONTROL IN A MULTI-CENTER RETROSPECTIVE COHORT OF PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED INFLAMMATORY ARTHRITIS Open
Background It is unknown whether particular presentations of immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) are associated with better cancer responses or faster time to arthritis control. Machine learning methods h…
View article: Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study
Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study Open
Immune checkpoint inhibitors (ICIs) have improved cancer outcomes but can cause severe immune-related adverse events (irAEs) and flares of autoimmune conditions in cancer patients with pre-existing autoimmune disease. The objective of this…
View article: Schnitzler syndrome
Schnitzler syndrome Open
A woman in her late 40s with a history of psoriatic arthritis presented to us with fever, migratory rash, cervical and axillary lymphadenopathy, and generalised myalgia. Her symptoms did not improve with steroids and her inflammatory marke…
View article: Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis Open
View article: 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases Open
Objective To provide evidence‐based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This guideline follows American College of Rheumatology (ACR) policy guiding …
View article: 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases Open
Objective To provide evidence‐based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs). Methods This guideline follows American College of Rheumatology (ACR) policy guiding …
View article: Issue Information
Issue Information Open
View article: Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications
Long COVID and rheumatology: Clinical, diagnostic, and therapeutic implications Open
View article: American College of Rheumatology Guidance for <scp>COVID</scp>‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5
American College of Rheumatology Guidance for <span>COVID</span>‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5 Open
Objective To provide guidance to rheumatology providers on the use of COVID‐19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was assembled that included 9 rheumatologists/immunologists, 2 in…
View article: 1260 Comparative safety and effectiveness of IL6R inhibitors, TNF inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
1260 Comparative safety and effectiveness of IL6R inhibitors, TNF inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis Open
Background Immune checkpoint inhibitor associated arthritis (ICI-A) affects 4% of ICI-treated cancer patients and often persists, even after ICI cessation. Given its long duration, it is important to identify effective treatments that do n…
View article: Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group
Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group Open
View article: Long COVID: defining the role of rheumatology in care and research
Long COVID: defining the role of rheumatology in care and research Open